Otonomy
ProfileJobs

Otonomy

Suggest Edit
    • Healthbiotechdrug developmentpharma

    Otonomy is a biopharmaceutical company developing and commercializing treatments for diseases of the inner and middle ear. The Company has developed a proprietary technology that is designed to deliver a drug that is retained in the ear for an extended period of time following a single local administration. Utilizing this technology, Otonomy has advanced multiple product candidates into development and launched its first product, OTIPRIO®.

    OTIPRIO is a single-dose, physician-administered antibacterial and the first product approved by the FDA for the treatment of pediatric patients with bilateral otitis media with effusion undergoing ear tube placement.

    Revenue(FY, 2017)
    $1.2 M
    Market capitalization(2018-06-14)
    $133 M
    Type
    Public
    HQ
    San Diego, US
    Founded
    2008
    Size (employees)
    139 (est)
    Website
    otonomy.com
    Otonomy was founded in 2008 and is headquartered in San Diego, US
    Report incorrect company information

    Key People/Management at Otonomy

    Paul Cayer

    Paul Cayer

    Chief Financial and Business Officer

    Otonomy Office Locations

    Otonomy has an office in San Diego
    San Diego, US (HQ)
    6275 Nancy Ridge Dr
    Show all (1)
    Report incorrect company information

    Otonomy Financials and Metrics

    Otonomy Financials

    Otonomy's revenue was reported to be $1.24 m in FY, 2017
    USD

    Revenue (Q1, 2018)

    		301 k

    Gross profit (Q1, 2018)

    		29 k

    Gross profit margin (Q1, 2018), %

    		9.6%

    Net income (Q1, 2018)

    		(11.4 m)

    EBIT (Q1, 2018)

    		(11.8 m)

    Market capitalization (14-Jun-2018)

    		133 m

    Closing share price (14-Jun-2018)

    		4.4

    Cash (31-Mar-2018)

    		23.2 m
    Otonomy's current market capitalization is $133 m.
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Revenue

    		683 k1.2 m

    Cost of goods sold

    		1.7 m3.1 m

    Gross profit

    		(981 k)(1.9 m)

    Gross profit Margin, %

    		(144%)(151%)
    Quarterly
    USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018

    Revenue

    		13 k76 k321 k358 k326 k301 k

    Cost of goods sold

    		9 k395 k351 k463 k397 k272 k

    Gross profit

    		4 k(319 k)(30 k)(105 k)(71 k)29 k

    Gross profit Margin, %

    		31%(420%)(9%)(29%)(22%)10%
    show all
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Cash

    		139.8 m158.7 m24.2 m18.5 m

    Accounts Receivable

    		91 k107 k

    Inventories

    		1.6 b5.3 m1.4 m6 k

    Current Assets

    		157.7 m188.2 m202.2 m122.4 m
    Quarterly
    USDQ1, 2018

    Cash

    		23.2 m

    Accounts Receivable

    		133 k

    Current Assets

    		112.7 m

    PP&E

    		4.5 m
    show all
    Annual
    USDFY, 2014FY, 2015FY, 2016FY, 2017

    Net Income

    		(42.9 m)(61.7 m)(110.6 m)(90.1 m)

    Depreciation and Amortization

    		213 k358 k708 k1.3 m

    Inventories

    		(1.4 m)153 k

    Accounts Payable

    		(309 k)1.7 m(2.2 m)(398 k)
    Quarterly
    USDQ3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

    Net Income

    		(29.7 m)(27.6 m)(27.1 m)

    Inventories

    		614 k913 k1.7 m1.2 m1.2 m

    Accounts Payable

    		1.7 m1.9 m4 k2.1 m2.4 m800 k934 k212 k1.3 m
    show all
    USDY, 2018

    Financial Leverage

    		1.1 x
    Show all financial metrics

    Otonomy Operating Metrics

    FY, 2016

    Patents Pending

    		115

    Phase II Trials Products

    		2

    Phase III Trials Products

    		2

    Preclinical Phase Products

    		1
    Show all operating metrics
    Report incorrect company information

    Competitors

    MyoKardia
    Health - Public
    Athersys
    Health - Public
    Ironwood Pharmaceuticals
    Health - Public
    Neurocrine Biosciences
    Health - Public
    Compare competitors

    Otonomy Online and Social Media Presence

    Embed Graph
    Report incorrect company information

    Otonomy News and Updates

    December 07, 2017

    Ultimate Analysis on Meniere ’s disease Market & Global Forecast to 2023

    Meniere’s disease market Analysis, by diagnosis (hearing assessment, balance assessment, and others), by treatment (medication, surgery, and others), by end user & is to Grow with USD 6380.3 Million, 8.5% of CAGR Posted via Industry Today. Follow us on Twitter @IndustryToday
    November 14, 2017

    Magnificent Expansion of Meniere ’s disease Market: Valuation USD 6380.3 Million, 8.5% of CAGR By 2023

    Market Research Future published a research report on “Meniere’s Disease Market Research Report- Global Forecast till 2023“– Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday
    Report incorrect company information
    Download PDF